Resumen de acción OPNT
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Competidores de Opiant Pharmaceuticals, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.65 |
| 52 Week High | US$28.15 |
| 52 Week Low | US$7.34 |
| Beta | 0.83 |
| 1 Month Change | 3.10% |
| 3 Month Change | 2.38% |
| 1 Year Change | -22.31% |
| 3 Year Change | 70.80% |
| 5 Year Change | 1.77% |
| Change since IPO | -82.79% |
Noticias y actualizaciones recientes
Recent updates
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates
Aug 13
Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment
Aug 08Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate
Aug 05Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts
Mar 21Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 19These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well
Nov 17Opiant Pharmaceuticals: Assessing Recent Insider Buying
Sep 19Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts
Aug 07Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)
Jun 09The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts
Mar 06News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts
Mar 05Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.
Jan 27Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003
Dec 14Opiant Pharmaceuticals receives $50M in convertible debt financing
Dec 10Rentabilidad de los accionistas
| OPNT | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | -1.3% | 0.7% | 2.9% |
| 1Y | -22.3% | 10.8% | 22.2% |
Rentabilidad vs. Industria: OPNT obtuvo unos resultados inferiores a los del sector US Pharmaceuticals , que el año pasado arrojó un rendimiento del 9.7%.
Rentabilidad vs. Mercado: OPNT obtuvo unos resultados inferiores a los del mercado US, que fue del 19.3% el año pasado.
Volatilidad de los precios
| OPNT volatility | |
|---|---|
| OPNT Average Weekly Movement | 1.5% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: OPNT no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de OPNT ha disminuido de 19% a 1% en el último año.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2005 | 38 | Roger Crystal | www.opiant.com |
Resumen de fundamentos de Opiant Pharmaceuticals, Inc.
| Estadísticas fundamentales de OPNT | |
|---|---|
| Capitalización bursátil | US$108.80m |
| Beneficios(TTM) | -US$33.09m |
| Ingresos (TTM) | US$22.34m |
4.9x
Ratio precio-ventas (PS)-3.3x
Ratio precio-beneficio (PE)¿Está OPNT sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de OPNT | |
|---|---|
| Ingresos | US$22.34m |
| Coste de los ingresos | US$29.45m |
| Beneficio bruto | -US$7.11m |
| Otros gastos | US$25.97m |
| Beneficios | -US$33.09m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -6.28 |
| Margen bruto | -31.85% |
| Margen de beneficio neto | -148.12% |
| Ratio deuda/patrimonio | 67.1% |
¿Cómo se ha desempeñado OPNT a largo plazo?
Ver rendimiento histórico y comparativa